Notably, the combined therapeutic effect was eliminated when the GL261 GBM tumor–bearing mice were depleted of CD8+ T cells (45.5 days in oeTRAF3 + PD-L1 mAb mice vs. 37 days in oeTRAF3 + PD-L1 mAb + CD8α mAb mice) (Supplemental Figure 8M). This evidence concerns the gene CD8A and glioblastoma.